Locations:
Search IconSearch

Ophthalmology Research

Eye drops

Hypertension Drug Losartan Reverses Scarring and Restores Vision After Cornea Damage

Studies indicate dramatic results when used topically with or without corticosteroids

22-EYE-3141638 CQD-EYP-1901 with vorolanib for maintenance of nAMD

DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD

53% of participants didn’t need anti-VEGF for six months or longer

22-EYE-3049477 New findings in retinal regeneration-Perkins-650×450-4

Restoring the Retina: How to Regenerate Photoreceptors in Inherited Retinal Dystrophy

Notch pathway inhibition preserves retinal neurons and promotes regrowth in zebrafish

22-EYE-2952199 CQD-Fixation eye movement abnormalities in amblyopia-Ghasia-650×450

Amblyopia: Eye Movement Recordings Enhance Understanding of Visual Deficits

Patients frequently have problems with depth perception and interocular suppression

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Nicole Bajic, MD

3D Viewing System Improves Surgical-Field-Based Visualization of iOCT Data

Surgeons also report benefits of integrated heads-up display

22-EYE-2826711 CQD_fig 1_Cornea Service – Grants_650x450_hero

Nine NIH R01 and Equivalent Grants Help Cleveland Clinic Researchers Advance Cornea Care

Among latest findings: Topical losartan helps reduce corneal scarring after injury

LASIK surgery

Corneal Epithelial Thickness Mapping May Change Patients’ Eligibility for Refractive Surgery

Study finds that 11% of those originally deemed ineligible for LASIK are now candidates

Eye chart

One Step Closer to a Drug Preventing Retinopathy of Prematurity

Artificially stabilizing hypoxia-inducible factor may stop the damaging effects of hyperoxia in preterm infants

Gene therapy surgery

Gene Therapy Surgery: Potential Next Frontier in Geographic Atrophy

Can a single subretinal injection provide effective treatment?

21-EYE- 2468445- CQD – Faricimab in Neovascular

Effect of New Therapy Lasts Longer for Patients with Neovascular Age-Related Macular Degeneration

Faricimab every 16 weeks offers similar benefits as aflibercept every eight weeks

BackPage 2 of 5Next

Advertisement

Ad